Aptose Biosciences (APTO) Projected to Post Quarterly Earnings on Tuesday

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) is anticipated to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Aptose Biosciences to post earnings of ($1.21) per share for the quarter.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $3.69 on Monday. The company has a market capitalization of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14. The stock’s 50 day moving average price is $4.84 and its 200 day moving average price is $7.76. Aptose Biosciences has a 52 week low of $2.39 and a 52 week high of $51.61.

Wall Street Analyst Weigh In

Several brokerages have recently commented on APTO. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. Finally, StockNews.com initiated coverage on Aptose Biosciences in a report on Wednesday, March 5th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $130.00.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.